skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

The treatment of diabetic foot infections: focus on ertapenem

Review

(3755) Views  (1612) Full article downloads

Authors: Michael Edmonds

Published Date November 2009 Volume 2009:5 Pages 949 - 963
DOI: http://dx.doi.org/10.2147/VHRM.S3162

Michael Edmonds

Diabetic Foot Clinic, King’s College Hospital, Denmark Hill, London, UK

Abstract: Clinically, 3 distinct stages of diabetic foot infection may be recognized: localized infection, spreading infection and severe infection. Each of these presentations may be complicated by osteomyelitis. Infection can be caused by Gram-positive aerobic, and Gramnegative aerobic and anaerobic bacteria, singly or in combination. The underlying principles are to diagnose infection, culture the bacteria responsible and treat aggressively with antibiotic therapy. Localized infections with limited cellulitis can generally be treated with oral antibiotics on an outpatient basis. Spreading infection should be treated with systemic antibiotics. Severe deep infections need urgent admission to hospital for wide-spectrum intravenous antibiotics. Clinical and microbiological response rates have been similar in trials of various antibiotics and no single agent or combination has emerged as most effective. Recently, clinical and microbiological outcomes for patients treated with ertapenem were equivalent to those for patients treated with piperacillin/tazobactam. It is also important to judge the need for debridement and surgery, to assess the arterial supply to the foot and consider revascularization either by angioplasty or bypass if the foot is ischemic. It is also important to achieve metabolic control. Thus infection in the diabetic foot needs full multidisciplinary treatment.

Keywords: diabetes, foot, infection, antibiotics, ertapenem








Readers of this article also read:

Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Berberine: metabolic and cardiovascular effects in preclinical and clinical trials
Aspirin and clopidogrel hyporesponsiveness and nonresponsiveness in patients with coronary artery stenting
Mitigating micro- and macro-vascular complications of diabetes beginning in adolescence
Management of hypertension with fixed dose combinations of candesartan cilexetil and hydrochlorothiazide: patient perspectives and clinical utility
Nitric oxide and coronary vascular endothelium adaptations in hypertension
ABO and rhesus blood group distribution in Kurds
Impact of a diabetic foot care education program on lower limb amputation rate
Neuropathic diabetic foot ulcers – evidence-to-practice
Cardiac ryanodine receptor in metabolic syndrome: is JTV519 (K201) future therapy?
  • Join ISVH

    Be part of the World's leading experts in vascular health by joining the International Society of Vascular Health (ISVH)

  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University